Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,564,883 papers from all fields of science
Search
Sign In
Create Free Account
darusentan
Known as:
(+)-(S)-2-((4,6-dimethoxy-2-pyrimidinyl)oxy)-3-methoxy-3,3-diphenylpropionic acid
, benzenepropanoic acid, alpha-((4,6-dimethoxy-2-pyrimidinyl)oxy)-beta-methoxy-beta-phenyl-, (S)-
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Broader (3)
Endothelin receptor antagonist
Phenylpropionates
Pyrimidines
Narrower (1)
LU 135252
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Divergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial
G. Bakris
,
L. Lindholm
,
+6 authors
Michael A. Weber
Hypertension
2010
Corpus ID: 207722663
Patients with resistant hypertension are at increased risk for cardiovascular events. The addition of new treatments to existing…
Expand
Highly Cited
2010
Highly Cited
2010
Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
J. Hartman
,
K. Brouwer
,
A. Mandagere
,
L. Melvin
,
R. Gorczynski
Canadian journal of physiology and pharmacology
2010
Corpus ID: 28285753
To evaluate potential mechanisms of clinical hepatotoxicity, 4 endothelin receptor antagonists (ERAs) were examined for substrate…
Expand
Review
2010
Review
2010
Benefits from Treatment and Control of Patients with Resistant Hypertension
M. Doumas
,
V. Papademetriou
,
+5 authors
C. Zamboulis
International journal of hypertension
2010
Corpus ID: 10061056
Resistant hypertension is commonly found in everyday clinical practice. However, the risks of resistant hypertension, as well as…
Expand
Highly Cited
2009
Highly Cited
2009
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
Michael A. Weber
,
H. Black
,
+7 authors
L. Lindholm
The Lancet
2009
Corpus ID: 7099160
Highly Cited
2007
Highly Cited
2007
Efficacy and Safety of Darusentan in Patients With Resistant Hypertension: Results From a Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Study
H. Black
,
G. Bakris
,
+9 authors
M. Gerber
Journal of clinical hypertension
2007
Corpus ID: 24092437
In this phase 2, randomized, double‐blind, placebo‐controlled forced dose‐titration study, 115 patients with resistant…
Expand
Review
2006
Review
2006
Profile of Past and Current Clinical Trials Involving Endothelin Receptor Antagonists: The Novel “-Sentan” Class of Drug
B. Battistini
,
N. Berthiaume
,
N. Kelland
,
D. Webb
,
D. Kohan
Experimental biology and medicine
2006
Corpus ID: 13399863
Since its initial characterization in 1988, over 18,236 papers, including 2,485 reviews, have been published in the endothelin…
Expand
2005
2005
Endothelin-1 inhibits the neuronal norepinephrine transporter in hearts of male rats.
J. Backs
,
Elke Bresch
,
M. Lutz
,
A. Kristen
,
M. Haass
Cardiovascular research
2005
Corpus ID: 13523720
Highly Cited
2004
Highly Cited
2004
Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo…
I. Anand
,
J. McMurray
,
+5 authors
T. Lüscher
The Lancet
2004
Corpus ID: 38506862
Highly Cited
2002
Highly Cited
2002
Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ETA) Receptor Blockade in Chronic Heart Failure: The Heart Failure ETA Receptor Blockade Trial (HEAT)
T. Lüscher
,
F. Enseleit
,
+10 authors
F. Ruschitzka
Circulation
2002
Corpus ID: 8410694
Background—The endothelin (ET-1) system is activated in chronic heart failure (CHF). Whether, what type, and what degree of…
Expand
Highly Cited
2002
Highly Cited
2002
Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension.
R. Nakov
,
E. Pfarr
,
S. Eberle
American journal of hypertension
2002
Corpus ID: 21369240
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE